Performance Evaluation of an Automated Neurofilament Light Chain Immunoassay
The Journal of Applied Laboratory Medicine · 01.07.2026 · 11 (4) · 844-856
DOI: 10.1093/jalm/jfag041 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 21.04.2026. Verfasst von Sarmistha Ray und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Development, Siemens Healthcare Diagnostics Inc., Tarrytown, NY, United States. Hauptthemen laut MEDLINE: Neurofilament Proteins, Multiple Sclerosis. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siemens Healthcare Diagnostics Inc., Novartis Pharma AG.
Abstract (Originalsprache)
Background
Increased neurofilament light chain (NfL) in cerebrospinal fluid and blood indicates recent neuroinflammatory damage and is prognostic of disease worsening (JAMA Neurol 2023;80:1317–25). These studies evaluate the analytical performance of the Siemens Healthineers Atellica IM NfL assay, testing serum and plasma, on the Atellica IM analyzer.
Methods
Detection capability, linearity, dilution recovery, precision, interfering substance testing, specimen equivalence, method comparison studies, and determination of expected values are all described and performed according to CLSI standards.
Results
The limit of blank, detection, and quantitation were 1.5, 2.0, and 3.0 pg/mL, respectively. The analytical measuring interval was 3.0 to 300.0 pg/mL with on-board dilutions extending the reportable range to 3000 pg/mL. Repeatability and within-lab precision ranged from 0.9% to 5.7% CV and 1.5% to 8.6% CV, respectively. No significant interference was detected for biotin or 38 other substances. Serum SST and plasma EDTA samples provided equivalent NfL results. Comparison of the NfL assay across Siemens Healthineers platforms (Atellica IM, ADVIA Centaur XP/XPT systems) showed strong alignment; the Atellica IM NfL assay also strongly aligns to the early phase certified reference material (Clin Chem Lab Med 2023;61:1245–54). Age-specific expected values for healthy adults were provided, with an overall central 95th percentile range of 3.7 to 18.9 pg/mL.
Conclusion
The Siemens Healthineers Atellica IM NfL assay demonstrated strong performance in all categories of assay development and verification; importantly, results from both healthy and multiple sclerosis patients fall within the reportable range. The Atellica IM NfL assay is for in vitro diagnostic use in the quantitative measurement of NfL in human serum and plasma (EDTA) using the Atellica IM analyzer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Research & Development, Siemens Healthcare Diagnostics Inc., Tarrytown, NY, United States.
- Department of Medical Affairs, Siemens Healthcare Diagnostics Inc., Tarrytown, NY, United States.
- Novartis Pharma AG, Clinical Development and Biostatistics Neuroscience, Basel, Switzerland.
Förderung
- Siemens Healthcare Diagnostics Inc.
- Novartis Pharma AG
Zitieren
APA
Ray, S., Fayyad, R., Lange, S., Abou-Diwan, C., Kukkaro, P., Häring, D. A., Gee, M., Wilson, J. E., & Merabet, E. (2026). Performance Evaluation of an Automated Neurofilament Light Chain Immunoassay. The Journal of Applied Laboratory Medicine, 11(4), 844-856. https://doi.org/10.1093/jalm/jfag041
Vancouver
Ray S, Fayyad R, Lange S, Abou-Diwan C, Kukkaro P, Häring DA, et al. Performance Evaluation of an Automated Neurofilament Light Chain Immunoassay. The Journal of Applied Laboratory Medicine. 2026;11(4):844-856. doi:10.1093/jalm/jfag041
BibTeX
@article{Ray2026,
author = {Ray, Sarmistha and Fayyad, Rana and Lange, Sascha and Abou-Diwan, Charbel and Kukkaro, Petra and Häring, Dieter A and Gee, Matthew and Wilson, JoDell E and Merabet, Eddine},
title = {Performance Evaluation of an Automated Neurofilament Light Chain Immunoassay},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
volume = {11},
number = {4},
pages = {844--856},
doi = {10.1093/jalm/jfag041}
}
EUVIMED